25 news items
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ABBV
18 Jun 24
and not greater than baseline, RBS of 0 and endoscopic subscore ≤1 without friability) at week 12. Secondary endpoints include clinical response (decrease
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
ABBV
COP
MRO
17 Jun 24
response
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
ABBV
14 Jun 24
in any way with Tutanota, its offer, or the offer documents. AbbVie recommends that AbbVie shareholders do not tender their shares in response
v5h5kp neqjjd1g3cn5hm4gykx82vgw5n3hnwp9ja56u9
ABBV
11 Jun 24
with the response
q2gqz4ghdqmifdrq 7owy
ABBV
ABOS
ALXO
6 Jun 24
on Jun 5 in response to the encouraging news. Year to date, the stock has jumped 23.5% against the industry's 5.6% decline
qcdjz49yr9qadwwbluxfhnj5qk3gy70q3a4l16bwp1ez
ABBV
6 Jun 24
).
The study met its primary endpoint with an objective response rate (ORR) of 51.9%.
In addition, the median duration of response (DOR), a key
vnw9llo7333yz1v7a3rln9mu1qbzu99t3h083r9ojbr4atpygx1u75ce1g
ABBV
6 Jun 24
PICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future
9g6dx42l7vaqvljrl8s7aqml81l
ABBV
6 Jun 24
met its primary endpoint of objective response rate (ORR)Data
55pk3ucl4xynqvhtkm8xqu2bzlbcxc87irws4ujjvvql2wrsgrrdsnbv7
ABBV
6 Jun 24
and supervisors perceive their migraine attacks as an excuse to dismiss responsibilities at work.4,5
9y6l9yse4k84cguqmsif7a2tpnljnzfedicv
ABBV
5 Jun 24
.
The dual primary end points are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR
2uuhb8y6u
ABBV
5 Jun 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts
58ocq5tmjqy6oid 08mwe1
ABBV
4 Jun 24
polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one
1i5ul 28hwi
ABBV
4 Jun 24
establishedTell your specialist if you are on therapy used to decrease the body's immune response
3upozr6snj4wf0
ABBV
ALXO
ANVS
3 Jun 24
UC patients who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended
gw2 6vaqdbvbo7bbn1mmmb6o4t6ae2skuw5v2pkh10fc
ABBV
31 May 24
an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended induction dose is 1200 mg intravenous
olcjpdjqctyr7pgal90yqz5cqoahtlksu8f
ABBV
CYTO
ONCY
24 May 24
expansion and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois. "The two
253hq01z7t2o lbhkbz22
ABBV
17 May 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts
q4zf0rampjdeql5k8jvcc
ABBV
17 May 24
Ulcerative Colitis Who Did Not Achieve Clinical Response to Initial 12-Week Induction Therapy